Rare lung disease shows hidden diversity despite identical genes
Researchers identified six distinct disease patterns in alpha-1 antitrypsin deficiency, even among patients with the same genetic mutation. The finding suggests personalized treatment approaches could improve outcomes—a shift that matters for rare disease drug developers, insurers evaluating coverage, and clinicians designing monitoring protocols.
Originaltitel: Clinical phenotypes in α
Alfa-1-antitrypsinbrist (AATD) visar sig ha sex distinkta kliniska fenotyptäer trots samma genetiska underlag, vilket öppnar vägen för personifierad behandlingsstrategi. KU Leuven identifierade dessa fenotyper genom klusteranalys på data från den europeiska forskarsamarbetet EARCO med ett F1-värde på 0,926. Diagnosalder, lungfunktion och tobaksexposition framstod som de viktigaste faktorerna för att skilja fenotyperna åt, vid sidan av själva genotypen. Upptäckten signalerar att miljö- och epigenetiska faktorer spelar minst lika stor roll som monogenen arv för sjukdomsmanifestationen. För leverantörer av diagnostik och terapi betyder detta att ensidig genotypbaserad stratifiering är otillräcklig — framtida läkemedelsutveckling måste adressera specifika fenotyper snarare än diagnosen i stort. Longitudinell uppföljning av dessa patientgrupper blir kritisk för att validera behandlingsrespons och därmed påskynda klinisk tillämpning.
BACKGROUND: α-1 antitrypsin deficiency (AATD) is a rare, monogenic disorder predisposing individuals to liver and lung diseases. Yet, even within the same genotype, AATD is very heterogeneous in clinical presentation. This heterogeneity suggests a complex interplay of environmental and (epi)genetic factors, highlighting the need for a detection and study of clinical phenotypes. METHODS: Here, we performed a cluster analysis using baseline data from the European Alpha-1 Research Collaboration (EARCO) to identify distinct clinical phenotypes in AATD. RESULTS: We identified six clusters of AATD clinical phenotypes using K-prototypes with a cross-validated weighted F1 score of 0.926. Moreover, using a trained random forest classifier, we identified age at diagnosis, lung function and tobacco consumption as the most important features in distinguishing these clusters, in addition to the AATD-associated genotype. CONCLUSIONS: Overall, these findings underscore the fact that, beyond genotype, a multitude of other factors significantly influence AATD clinical phenotypes. Accordingly, this emphasises the importance of integrating (epi)genetic, environmental and behavioural data in future fundamental and translational research to unravel the complex mechanisms underlying patient heterogeneity. Moreover, longitudinal follow-up of individuals allocated to these clusters will help to better understand disease progression and to assess the potential benefits of specific therapies in different phenotypes.